Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Arbutus Biopharma Corp (ABUS)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M | $10.7M | $1.5M | $23.3M | $15.0M | $15.5M | $14.1M | $16.8M |
| Research & development | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M | $49.3M | $57.6M | $57.9M | $62.7M | $61.3M | $51.5M | $38.7M | $21.5M | $18.0M | $20.1M |
| Operating expenses | $52.2M | $82.5M | $96.2M | $104.5M | $84.5M | $64.7M | $149.9M | $95.7M | $121.6M | $493.1M | $127.2M | $48.4M | $27.6M | $27.1M | $27.5M |
| Operating income | −$38.2M | −$76.3M | −$78.1M | −$65.5M | −$73.5M | −$57.8M | −$143.9M | −$89.8M | −$110.9M | −$491.6M | −$103.9M | −$33.4M | −$12.2M | −$12.9M | −$10.7M |
| Net income | −$33.5M | −$69.9M | −$72.8M | −$69.5M | −$76.2M | −$63.7M | −$153.7M | −$57.1M | −$84.4M | −$384.2M | −$62.7M | −$38.8M | −$14.1M | $29.6M | −$10.1M |
| Basic EPSper diluted share | -$0.17 | -$0.38 | -$0.44 | -$0.46 | -$0.83 | -$1.00 | -$2.89 | -$1.21 | -$1.56 | -$7.24 | -$1.38 | -$1.80 | -$0.92 | $2.16 | -$0.89 |
| Diluted EPSper diluted share | -$0.17 | -$0.38 | -$0.44 | -$0.46 | -$0.83 | -$1.00 | -$2.89 | -$1.21 | -$1.56 | -$7.24 | -$1.38 | -$1.80 | -$0.92 | $2.07 | -$0.89 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 4, 2025Form 4 · 10b5-1 | HASTINGS DAVID CChief Financial Officer | SellCommon Shares | 22.2K | $3.28 | $72.8K | 159.7K |
| Feb 4, 2025Form 4 · 10b5-1 | Sims KarenChief Medical Officer | SellCommon Shares | 19.3K | $3.28 | $63.5K | 106.2K |
| Feb 4, 2025Form 4 · 10b5-1 | McElhaugh Michael J.Interim President & CEO | SellCommon Shares | 23.8K | $3.28 | $78.0K | 1.48M |
| Feb 4, 2025Form 4 · 10b5-1 | Naftzger J. ChristopherGeneral Counsel and CCO | SellCommon Shares | 11.3K | $3.28 | $37.2K | 86.2K |
| Aug 14, 2024Form 4 | MANCHESTER KEITH SDirector | SellCommon Shares | 8.8K | $3.69 | $32.6K | 46.1K |